ASX Announcements
Company Presentation, Chairman's Address to Shareholders
- Nov 14, 2024
- 18 pages
August 2023
Imugene in $60m cash call for new licensing deal; Bells on ticket
The money will be used to fund the acquisition of a licence for Precision Biosciences’ azer-cel allogeneic cancer treatment.
- Sarah Thompson, Kanika Sood and Emma Rapaport
June 2023
- Opinion
- Sharemarket
It’s time to ban penny stocks from Australia’s flagship share index
The collapse of Lake Resources and poor performance of BrainChip and Imugene shows why there’s no place for penny stocks in a serious sharemarket index.
- Tom Richardson
September 2022
- Exclusive
- Funding
What tech wreck? This start-up is already rehiring
Two months after laying off half its employees, HealthMatch has closed a funding round, which will allow it to rehire some people and pursue US growth.
- Updated
- Paul Smith
June 2022
Imugene soars 45pc on gastric cancer trial results
Imugene is providing fresh hope for gastric cancer patients thanks to the development of an oncolytic virus that infects and breaks down cancer cells,
- Updated
- Yolanda Redrup
October 2021
Sector’s stars turn up for BioShares’ David Blake
As of Thursday evening, $106,870 had been raised to cover the costs of David Blake’s in-home nursing support through a crowdfunding page.
- Myriam Robin
July 2021
Buy, hold, sell: Imugene, Liontown Mesoblast, Kogan, Dusk
The best and worst small-cap performers from FY21.
May 2021
Imugene’s $2.3b valuation raises eyebrows
The biotech has seen insider selling this week, sometimes to fund option purchases, sometimes not. Another shareholder works at its key partner.
- Tom Richardson
Imugene pens global patent licensing deal with LA-based research centre
ASX-listed immuno-oncology company has entered a deal with City of Hope for a novel cancer therapy targeting solid tumours that would otherwise be tough to treat.
- Carrie LaFrenz
January 2021
Cancer biotech Chimeric soars 50pc on debut
Champagne corks popped for investors in emerging cancer therapy company Chimeric Therapeutics, whose shares soared more than 60 per cent in opening trade.
- Yolanda Redrup
November 2019
Bell Potter, Aurenda raising for Imugene
Biopharmaceutical company Imugene is looking to raise up to $24.6 million in an equity raising targeted at institutions.
- Sarah Thompson, Anthony Macdonald and Tim Boyd
June 2018
Imugene to raise $20m, fund trials at Ohio State University, Mayo Clinic
Cancer vaccine hopeful Imugene is seeking funding clinical programs at Ohio State University and the prestigious Minnesota-based Mayo Clinic.
- Updated
- Carrie LaFrenz
November 2017
Another Bell Potter raising, this time Imugene
Cancer vaccine hopeful Imugene Ltd is in front of investors seeking an equity injection.
- Updated
- Sarah Thompson, Anthony Macdonald and Joyce Moullakis
November 2008
Big bucks for executives at the small end of town
As shareholders vote down the big executive pay packets of top 100 giants like Boral and Transurban, spare a thought for the investors in Raw Capital Partners, a Brisbane-based information technology and corporate advisory firm.
- John Stensholt and Damon Kitney
September 2008
Imugene (IMU)
Biopharmaceuticals developer Imugene recently reported a decrease in its loss after tax to $1.91 million from a loss of $2.30 million a year earlier.
- Peter Wells